CAS 1386874-06-1

Fórmula: C23H26N4O3

InChI: InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1

Clave InChI: ACCFLVVUVBJNGT-AWEZNQCLSA-N

SMILES: C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC

Samotolisib

CAS: 1386874-06-1

Samotolisib

Fórmula: C₂₃H₂₆N₄O₃

Pureza: ≥98%

Peso molecular: 406.48

Ref: 54-BUP13397

LY-3023414

CAS: 1386874-06-1

Fórmula: C₂₃H₂₆N₄O₃

Pureza: 98%

Forma y color: Solid

Peso molecular: 406.4775

Ref: IN-DA001900

Samotolisib

CAS: 1386874-06-1

(S)-8-(5-(2-Hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxypropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one

Fórmula: C₂₃H₂₆N₄O₃

Pureza: 98%

Peso molecular: 406.48

Ref: IN-DG630209

Samotolisib

CAS: 1386874-06-1

Samotolisib (LY3023414) inhibits PI3K, DNA-PK, mTOR; tested for solid tumors including breast and colon cancer.

Fórmula: C₂₃H₂₆N₄O₃

Pureza: 98.41% - 99.69%

Forma y color: Solid

Peso molecular: 406.4775

Ref: TM-T6883

Samotolisib

CAS: 1386874-06-1

Pureza: 98%

Peso molecular: 406.2

Ref: 10-F980066

Samotolisib

CAS: 1386874-06-1

Samotolisib is a novel drug that has been shown to inhibit tumor growth in vivo. Samotolisib was effective against tumors in a mouse xenograft model, as well as against both skin and bone cancer in mice. The molecular docking analysis suggests that samotolisib binds to the ATP-binding site of the enzyme ribonucleotide reductase (RNR), thereby inhibiting the production of DNA precursors required for protein synthesis. This inhibition leads to apoptosis and necrosis of tumor cells. Samotolisib has also been shown to induce autophagy and apoptosis in cultured human skin cells, suggesting it may have potential for treating skin cancers.

Fórmula: C₂₃H₂₆N₄O₃

Pureza: Min. 95%

Peso molecular: 406.48 g/mol

Ref: 3D-LFC87406